Parvovirus B19 (B19) is a single-stranded DNA virus, which preferentially replicates in erythroid progenitor cells. 1 In immunocompetent individuals, the majority of B19 infection is asymptomatic, and the most common clinical presentation in children is erythema infectiosum. 1 In contrast, in patients undergoing solid organ transplantation or hematopoietic stem cell transplantation (HSCT), refractory anemia is the predominant clinical manifestation. 2 In this patient population, B19 infection has also been associated with complications such as allograft dysfunction, hepatitis or myocarditis, but nonetheless, relatively little is known about B19 syndromes in transplanted patients. We report for the first time a patient undergoing allogeneic HSCT and suffering from B19 pneumonia, which was suspected since B19 genome was detected in lung tissue as well as in bronchoalveolar lavage (BAL) fluid and pleural effusion.
A 4-year-old boy was diagnosed with common acute lymphoblastic leukemia. The malignancy and two relapses were treated with standard chemotherapy according to ALL-BFM protocols. After a third relapse, the boy underwent haploidentical stem cell transplantation in March 1999. The conditioning regimen consisted of fludarabine (40 mg/m 2 /day for 5 days), thiotepa (2 mg/kg/ day for 5 days), OKT3 (0.1 mg/m 2 /day for 14 days), total body irradiation (cumulative dosage 12.6 Gy) and radioimmunotherapy (rhenium-188-anti-granulocyte antibody application, total splenic and bone marrow dosages 11.3 and 12.2 Gy, respectively), followed by the administration of 3.5 Â 10 7 CD34 þ cells per kg. In addition, as part of a clinical protocol, he received 10.3 Â 10 6 , 3.3 Â 10 6 and 33.8 Â 10 6 interleukin (IL)-2-activated natural killer cells on days þ 1, þ 42 and þ 111, respectively. IL-2 (1 Mio U/ m 2 ) was given every other day for a total of 30 days. Both donor and recipient screened seronegative for B19 5 months before transplantation. Engraftment (ANC4500/ mm 3 ) was documented on day þ 14, and continuous complete remission was achieved. Anti-infective prophylactic measures consisted of trimethoprim-sulfamethoxazole, metronidazole, itraconazole, oral acyclovir (40 mg/kg/ day) and regular administration of immunoglobulins (0.2 g/ kg). Owing to persistent fever, the boy received broadspectrum antibiotics and amphotericin B (3 mg/kg) until day þ 24. Routine PCR surveillance examination revealed transient viremia of B19 on day þ 22, but no clinical symptoms could be attributed to this episode. Control PCR 1 week later was negative, as were further controls performed every 3 weeks. In May 1999, skin rash, diarrhea and elevated liver enzymes suggested graft-versus-host disease (GvHD), which was histologically proven on colon and liver biopsies. Treatment consisted of high-dose steroids for 5 weeks. In addition, ganciclovir (5 mg/kg/ day) was started since the PCR for human herpesvirus-6 (HHV-6) was positive in liver tissue and blood. No other pathogen could be detected at that time, and PCR for HHV-6 was negative in serum controls. In July 1999, the boy developed dyspnea and coughing. His clinical situation deteriorated rapidly and he required mechanical ventilation. Chest radiographs and computer tomography (CT) scans of the lung revealed atypical pneumonia with diffuse bilateral, symmetric, alveolar infiltrates ( Figure 1 ). No pathogens were detected from peripheral blood or bone marrow, but the PCR for B19 was positive in lung tissue, BAL fluid and pleural effusion. Serum IgM for B19 was negative, and positive IgG titers were attributed to previous intravenous immunoglobulin administration. Histopathological examination of lung biopsy specimens revealed interstitial pneumonia, but no signs of GvHD or invasive fungal infection. Subsequently, the patient received intravenous immunoglobulins (1 g/kg/day for 6 days) and binterferon (10 MIU/day for 3 days). Since Aspergillus spp was detected in BAL, antimycotic therapy was intensified. Unfortunately, the boy died few days later due to respiratory failure. Autopsy revealed interstitial pneumonia with thickened alveolar septi, and the B19 genome was detected by PCR in heart, lung, spleen, liver, pancreas and in the gastrointestinal tract. In addition, scattered necrotic areas containing molds suggestive of invasive aspergillosis were found in the central areas of the lungs.
For detection of parvoviral genomes, quantitative PCR (TaqMan) was performed using primers and probes as described previously. 3 In brief, formaldehyde-fixed tissues were used for analysis and rehydrated before DNA extraction. For quantification of the number of viral genomes in relation to the number of cells in the respective tissue, the gene encoding human pyruvate dehydrogenase was submitted for quantitative PCR.
Infection with B19 is common in childhood, and approximately half of 15-year-old adolescents have specific anti-B19 antibodies. 1 The virus is spread by respiratory droplets, but may also be transmitted by blood products. 1 Whereas in healthy individuals, the majority of B19 infections remain asymptomatic, infection with B19 may lead to transient aplastic crisis in patients with increased erythropoiesis or to persistent anemia in immunocompromised patients. 1 Since large prospective studies are lacking, little is known about the incidence and clinical spectrum of B19 infection among transplanted patients. A recent review identified 98 patients with symptomatic B19 infection after transplantation. 2 The authors conclude that refractory anemia during the post-transplantation period is the predominant manifestation, which, in turn, is a common complication after transplantation. In addition, B19 infection has been associated with post transplant complications, such as allograft dysfunction, hepatitis, myocarditis and glomerulonephritis, and post transplant mortality directly attributed to B19 was estimated in 3%. 2 Whereas severe pulmonary complications due to B19 have not been reported in patients undergoing HSCT, pneumonia was diagnosed in a young boy with acute B19 infection after heart transplantation and in a 9-year-old girl with chronic B19 infection after lung transplantation. 4, 5 In the heart transplant patient, the diagnosis of acute B19 infection was made on the basis of fever, rash and a high IgM antibody level, and pneumonia was attributed to B19 infection since no other pathogen was detected. 4 The girl with chronic B19 infection after lung transplantation had persisting B19 viremia and suffered from recurrent nonregenerative anemia. During one episode of anemia, the girl developed pneumonia, and the B19 genome was detected in the BAL fluid. 5 However, it is important to note that the B19 genome may also be detected in BAL samples in patients after transplantation who do not suffer from pneumonia. 6 In our patient, we detected B19 DNA not only in the BAL fluid, but also in pleural exudate and, most importantly, in lung tissue, which has, to the best of our knowledge, not been reported in immunocompromised patients to date. Although we did not see a viral cytopathic effect in the lung specimen and immunohistochemistry for B19 was negative, the association of clinical symptoms, atypical CT scan and detection of B19 DNA in the lung tissue suggest that B19 was, at least in part, the direct cause of the pneumonia. The exact pathogenesis of severe pulmonary complications by B19 is unclear, and it may be speculated whether the damage is directly caused by a cytotoxic effect of the virus or by a yet-undefined aberrant host immune response triggered by B19. Although interstitial pneumonia due to non-human parvovirus is recognized in animals, the potential of B19 to directly infect pneumocytes remains unclear.
7 B19 DNA may persist lifelong in human tissue such as skin, synovia or liver, and recurrence of B19-related systemic diseases has been suggested in immunocompromised patients. 3, 8 The significance of a positive PCR finding, however, has to be determined by studies evaluating the prevalence of the B19 genome in healthy tissue. Notably, the B19 genome was detected in the patient's liver and gastrointestinal tract in autopsy, but not in the biopsy specimens obtained 3 months before. It can only be speculated whether this fact might be attributed to the transient viremia observed soon after transplantation. It is well known that the B19 genome can be detected in tissue without concurrent viremia as well as that negative serological test results during acute B19 infection can be seen in the first months after HSCT. 9, 10 It is not possible to determine whether the pulmonary complications in this case were associated with B19 (re-) infection or with re-activation of persistent infection. In this regard, chronic B19 infection has been described in several immunodeficiency conditions, such as in patients undergoing therapy for acute leukemia or bone marrow transplantation. 9 It is important to note that this patient was coinfected with Aspergillus spp, which, however, did not fully account for the respiratory failure since the extent of aspergillosis was very limited. Simultaneous infection with two pathogens often results in enhanced morbidity and mortality, in particular in immunocompromised patients. 9 Since control of B19 infection depends on effective host humoral response and no specific antiviral agent against B19 is available, immunoglobulins are suggested for treatment of Letter to the Editor symptomatic immunocompromised patients. 1 In addition, a candidate vaccine is currently under investigation and may be used for various risk groups. Unfortunately, immunoglobulins were ineffective in our patient, but the entity of B19 pneumonia after allogeneic HSCT has not been described before.
In summary, B19 infection after transplantation may cause severe pulmonary disease. Therefore, attention to infection-control practices and regular screening of blood products with respect to B19 are important in immunocompromised patients. It has to be noted that not all assays are capable of detecting the B19 genotypes 2 and 3. In addition, the search for B19 DNA should be conducted in any transplant patient with unexplained complications, such as respiratory distress. This will help to elucidate prevalence and spectrum of B19 disease, and will also give important information about the effect of prophylactic and therapeutic strategies. 
